Pharma Roundup: Pfizer's Acquisition Plans, Prasugrel's Big Day, and More

Pfizer CEO seeks big acquisition — In a much-discussed comment to the Financial Times, Pfizer’s CEO Jeff Kindler revealed his aspirations for revenue-boosting deals, large and small. As the Health Blog points out, the takeaway here is Kindler’s apparent willingness to pursue old-fashioned big acquisitions, at a time when most pharma companies seem interested in smaller purchases, if any. Derek Lowe at In the Pipeline is unimpressed. [Source: WSJ Health Blog]

Prasugrel to be reviewed on February 3 — The FDA has granted a formal hearing to the drug, a Lilly and Daiichi product currently languishing in a quagmire of delay. Lilly has high hopes for the drug. [Source: PharmaTimes]

Resolutions, predictions, and other New Year’s features — Bloggers love lists, and the dawn of 2009 brings us end-of-year/New Year features from many sites. Highlights include Fierce Biotech’s dire “Welcome to the valley of death” biotech check-in and John Mack’s cheeky “resolutions” for pharma marketers. [Source: FierceBiotech, Pharma Marketing Blog]

Pharmalot’s swan song — As many of you may know, Ed Silverman has penned the final post at pharmaceuticals blog Pharmalot . For the past two years, Ed has brought us sharp, savvy analysis of timely industry news, and Pharmalot has been a consistent voice of quality in the pharma blogosphere. Thank you, Ed… we wish you all the best! Pharmalot will be missed. [Source: Pharmalot]